The withdrawal comes after postmarketing studies showed that the risks of side effects were greater than the benefits.
Pfizer anticipates revenue growth, driven by oncology investments, M&A activities, and manufacturing optimization. See why ...
Pfizer has divested a $3.3 billion stake in Haleon, reducing its holding in the British consumer healthcare company.
The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...
This summary highlights major health news, including Bavarian Nordic's UNICEF agreement for mpox vaccines, Pfizer's ...